Our large-scale multi-omics analyses give you an unprecedented view into dynamic factors beyond the genome that modulate health, disease, and drug response.
Through our integrated multi-omics services, we generate greater biological insight from every sample to help you better understand disease and accelerate drug development.
As your partner for insights, we offer deep data analysis services to help you extract actionable discoveries from both large-scale and targeted multi-omics datasets.
Our team uses advanced AI and ML tools for multi-scale analyses to identify novel biomarkers, perform pathway mapping, uncover robust drug targets, and develop predictive models.
We leverage our in-house, longitudinal multi-omics & real-world database – generated from >56,000 human samples – for guided analyses curated to your research questions.
Sapient was founded on a core set of discovery values that we bring to every client collaboration, and that we believe are critical to accelerate drug development success.
We know our data drives your
decision-making and have capacity to ensure fast turnaround of results.
We believe it essential that you have full access to and ownership of your data and findings.
We utilize novel technologies and deep expertise to assay thousands of dynamic, non-genetic biomarkers.
Our team uses advanced statistical and ML tools to amalgamate multi-omics, preclinical, and clinical data with human health metadata.
Using Sapient’s proprietary Human Biology Database, comprised of multi-omics data from tens of thousands of biosamples with paired real-world data.
Sapient is a purpose-built biomarker discovery organization providing bespoke multi-omics services for metabolomics, lipidomics, and proteomics data generation and analysis.
Sapient’s next-generation, high throughput mass spectrometry systems capture diverse metabolite and lipid chemistries in a single run.
Sapient’s suite of panels enable targeted exploration of small molecules in specific chemical classes and commonly associated with health and disease.
Sapient’s mass spectrometry-based discovery proteomics method extends multi-omics insights with deep coverage of the blood and tissue proteome.
Sapient leverages its mass spectrometry systems for the quantitative measure of key proteins and PTMs in plasma, cells, and tissue.
Through NULISA™ assays, Sapient can provide highly quantitative measures of these markers to cover the complete dynamic range of proteins in biofluids.
Through our integrated multi-omics services, we generate greater biological insight from every sample to help you better understand disease and accelerate drug development.
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
© 2025 Sapient Bioanalytics, LLC. All rights reserved.
SAPIENT, the SAPIENT Logo, DYNAMIQ INSIGHTS ENGINE, and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC
